RVXCF - Resverlogix Corp.

Other OTC - Other OTC Delayed Price. Currency in USD

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403-254-9252
http://www.resverlogix.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. Donald J. McCaffreyCo-Founder, Pres, CEO & ChairmanN/AN/AN/A
Mr. Aaron Bradley Cann CA, CPA, CBVChief Financial OfficerN/AN/AN/A
Mr. Kenneth Eugene Lebioda BASr. VP of Bus. & Corp. Devel.N/AN/AN/A
Dr. Jan O. JohanssonSr. VP of Medical AffairsN/AN/AN/A
Dr. Michael SweeneySr. VP of Clinical Devel.N/AN/A1961
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.